(Q38226307)

31 August 2017

Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (English)

1 reference

head and neck squamous cell carcinoma

31 August 2017

1 reference

4

1 reference

31 August 2017

Francesco Perri

1

0 references

Roberto Pacelli

object named as

Roberto Pacelli

2

0 references

author name string

Giuseppina Della Vittoria Scarpati

3

1 reference

31 August 2017

Mario Giuliano

5

1 reference

31 August 2017

Francesco Caponigro

6

1 reference

31 August 2017

Stefano Pepe

7

1 reference

31 August 2017

27 January 2015

1 reference

31 August 2017

1 reference

31 August 2017

37

1 reference

31 August 2017

763-770

1 reference

31 August 2017

5

1 reference

Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy

31 August 2017

1 reference

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

21 January 2018

1 reference

EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

21 January 2018

1 reference

Signaling intricacies take center stage in cancer cells

21 January 2018

1 reference

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

21 January 2018

1 reference

Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma

21 January 2018

1 reference

The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.

21 January 2018

1 reference

Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis

21 January 2018

1 reference

Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis

21 January 2018

1 reference

Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance.

21 January 2018

1 reference

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial

21 January 2018

1 reference

Evidence-based radiation oncology in head and neck squamous cell carcinoma.

21 January 2018

1 reference

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.

21 January 2018

1 reference

Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma.

21 January 2018

1 reference

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells

21 January 2018

1 reference

Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release.

21 January 2018

1 reference

Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells

21 January 2018

1 reference

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

21 January 2018

1 reference

Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity.

21 January 2018

1 reference

Stress and radiation-induced activation of multiple intracellular signaling pathways

21 January 2018

1 reference

PIK3CA mutations in head and neck squamous cell carcinoma

21 January 2018

1 reference

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

21 January 2018

1 reference

Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer

21 January 2018

1 reference

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.

21 January 2018

1 reference

The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6.

21 January 2018

1 reference

Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction

21 January 2018

1 reference

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.

21 January 2018

1 reference

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

21 January 2018

1 reference

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

21 January 2018

1 reference

Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

Awakening guardian angels: drugging the p53 pathway

21 January 2018

1 reference

Live or let die: the cell's response to p53

21 January 2018

1 reference

The p53 network in head and neck cancer

21 January 2018

1 reference

Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a.

21 January 2018

1 reference

p53 has a direct apoptogenic role at the mitochondria

21 January 2018

1 reference

PUMA, a potent killer with or without p53

21 January 2018

1 reference

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

21 January 2018

1 reference

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

21 January 2018

1 reference

p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

21 January 2018

1 reference

A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology

21 January 2018

1 reference

Head and neck cancer: response to p53-based therapeutics

21 January 2018

1 reference

China approves first gene therapy

21 January 2018

1 reference

p53-based therapeutics for head and neck squamous cell carcinoma

21 January 2018

1 reference

Sensitization by glycerol for CDDP-therapy against human cultured cancer cells and tumors bearing mutated p53 gene

21 January 2018

1 reference

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma

21 January 2018

1 reference

Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma

21 January 2018

1 reference

Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

New Concepts for Translational Head and Neck Oncology: Lessons from HPV-Related Oropharyngeal Squamous Cell Carcinomas

21 January 2018

1 reference

High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma

21 January 2018

1 reference

New treatment strategies for HPV-positive head and neck cancer

21 January 2018

1 reference

Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer

21 January 2018

1 reference

Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial

21 January 2018

1 reference

A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies

21 January 2018

1 reference

7 January 2021

p53 and Ki-67 as markers of radioresistance in head and neck carcinoma

1 reference

7 January 2021

Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer

1 reference

7 January 2021

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

1 reference

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

7 January 2021

Therapeutic strategies for head and neck cancer based on p53 status

1 reference

7 January 2021

Molecular changes in the multistage pathogenesis of head and neck cancer

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.23837

1 reference

31 August 2017

1 reference